Baidu
map

EUR J NEUROL:缺血性卒中患者容易出现视力问题

2015-11-20 MedSci MedSci原创

长期随访发现有1/4的脑梗死患者报告脑梗死后出现视力问题。脑梗死后出现视力问题降低患者的生活质量,增加患者因脑梗死致残率。对于脑梗死后出现视力问题的患者,全面的诊断评估和有针对性的康复治疗是非常重要的。

挪威卑尔根大学临床医学系K M Sand和同事研究发现缺血性卒中患者的视力问题影响生活质量,导致患者残疾。研究结果在European Journal of Neurology在线发表。

背景:近年来有越来越多的患者脑梗死后出现视力问题。研究目的是探讨患者脑梗死后出现视力问题对生活质量和卒中后残疾的影响。

方法:研究纳入了2006年2月-2008年7月入住Haukeland大学医院神经科卒中单元的急性脑梗死患者。这项研究已经在NORSTROKE注册中心登记注册。

患者在卒中6个月或更长时间后填写调查问卷。调查问卷的内容包括15D©、EuroQol 5D(EQ-5D™)、HADS(Hospital Anxiety and Depression Scale ,医院焦虑和抑郁量表)、FSS(Fatigue Severity Scale,疲劳程度量表)和BI(Barthel Index ,Barthel指数)。

将所有受试者分成两组,观察组患者报告在脑梗死后出现视力问题,对照组患者报告在脑梗死后没有出现视力问题。

结果:研究发现328例受试者中有83例 (25.4%) 报告有视力问题。出现视力问题与以下三个因素有关联:老龄(观察组评价71.8岁,对照组平均66.5 岁, P = 0.001);住院时NIHSS(National Institutes of Health Stroke Scale,国家研究生健康中风量表)评分较高(观察组 5.9 ,对照组3.8,P<0.001);第7天mRS(modified Rankin Scale ,调整后的Rankin量表 )评分较高 (观察组 2.0,对照组 1.4,P<0.001);第7天BI较低 (观察组 85.7,对照组93.9, P=0.002)。

长期随访发现,相比较于对照组,观察组有以下特点:EQ-5D实用评分中位数较低(观察组0.62,对照组0.80,P<0.001);15D实用评分中位数较低 (观察组 0.73,对照组0.89,P < 0.001);HADS中位数较高(观察组12 ,对照组5,P<0.001);FSS评分中位数较高(观察组5.6,对照组4.3,P<0.001);BI中位数较低 (观察组95,对照组100,P<0.001)。

长期随访发现,自我报告患有视力问题的脑梗死患者的BI的所有子项评分均较低(P<0.001)。

结论:作者认为长期随访发现有1/4的脑梗死患者报告脑梗死后出现视力问题。脑梗死后出现视力问题降低患者的生活质量,增加患者因脑梗死致残率。对于脑梗死后出现视力问题的患者,全面的诊断评估和有针对性的康复治疗是非常重要的。

原始出处:

Sand K M, Wilhelmsen G, Naess H, et all. Vision problems in ischaemic stroke patients: effects on life quality and disability. EUR J NEUROL,23:1-7.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1892704, encodeId=331b1892e0498, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 27 22:02:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720076, encodeId=747b1e2007606, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Feb 28 10:02:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999602, encodeId=0b6a19996021e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Jan 06 01:02:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806049, encodeId=d0b818060493e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 14 13:02:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010335, encodeId=7d6520103350b, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sat Aug 13 04:02:00 CST 2016, time=2016-08-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1892704, encodeId=331b1892e0498, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 27 22:02:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720076, encodeId=747b1e2007606, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Feb 28 10:02:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999602, encodeId=0b6a19996021e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Jan 06 01:02:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806049, encodeId=d0b818060493e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 14 13:02:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010335, encodeId=7d6520103350b, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sat Aug 13 04:02:00 CST 2016, time=2016-08-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1892704, encodeId=331b1892e0498, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 27 22:02:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720076, encodeId=747b1e2007606, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Feb 28 10:02:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999602, encodeId=0b6a19996021e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Jan 06 01:02:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806049, encodeId=d0b818060493e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 14 13:02:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010335, encodeId=7d6520103350b, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sat Aug 13 04:02:00 CST 2016, time=2016-08-13, status=1, ipAttribution=)]
    2016-01-06 yinhl1978
  4. [GetPortalCommentsPageByObjectIdResponse(id=1892704, encodeId=331b1892e0498, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 27 22:02:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720076, encodeId=747b1e2007606, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Feb 28 10:02:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999602, encodeId=0b6a19996021e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Jan 06 01:02:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806049, encodeId=d0b818060493e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 14 13:02:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010335, encodeId=7d6520103350b, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sat Aug 13 04:02:00 CST 2016, time=2016-08-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1892704, encodeId=331b1892e0498, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Mar 27 22:02:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720076, encodeId=747b1e2007606, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sun Feb 28 10:02:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999602, encodeId=0b6a19996021e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Jan 06 01:02:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806049, encodeId=d0b818060493e, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 14 13:02:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010335, encodeId=7d6520103350b, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sat Aug 13 04:02:00 CST 2016, time=2016-08-13, status=1, ipAttribution=)]

相关资讯

Neurology:韩国轻中度饮酒可降低缺血性卒中的发生

目的:研究者进行了一项基于人群的病例对照研究,研究与西方酒精饮料偏好不同的韩国人在酒精摄入和缺血性卒中风险之间剂量反应关系,并且检测性别和缺血性卒中类型的影响。 方法:招募了年龄20岁以上首发卒中的患者1848名作为病例组。按照年龄(±3岁),性别及教育程度从第四和第五次韩国国家和营养调查中选取3589名无卒中的对照者与对照组进行配对。所有的受试者完成一项关于酒精摄入的结构性问卷调查的面谈。结果:

J Neurochem:区分缺血性卒中和出血性卒中的生物标记物:RBP4 和GFAP

快速区分急性缺血性脑卒中和出血性脑卒中是非常必要的,能够促进改善预后。研究者旨在识别新型的生物标记物区分卒中亚型,并比较其他已经描述过的生物标记物的诊断能力。应用177抗体库筛选缺血性脑卒中(36)和出血性卒中(10)患者的血浆样本,其中有11种在不同脑卒中亚型中,浓度不同,主要是趋化因子、生长因子和血管生成因子。从16名缺血性卒中和16出血性卒中患者中选出五种蛋白,及视黄醇结合蛋白4(RPB4)

Stroke:血浆D-二聚体浓度高,小心缺血性卒中!

流行病学研究已经证实,D-二聚体,纤维蛋白降解产物,是冠心病的危险标志物,但是对于中风的前瞻性数据是有限的。由于血栓形成是许多卒中发生的关键机制,因此研究人员在ARIC试验中研究了是否D-二聚体是缺血性卒中发生的危险标志物。研究人员在1992年至1995年测量11415例ARIC患者的D-二聚体,他们没有卒中和冠状动脉心脏疾病。随后研究人员跟踪调查了他们卒中,卒中亚型,和冠状动脉心脏疾病事件直至2

JACC:缺血性脑卒中的发生与吸食大麻是否有关?

近日,最新一项医学研究成果表明,在患有缺血性中风的患者中,定期吸食大麻的患者比没有吸食过大麻的更容易出现颅内动脉狭窄。据统计,在 2005到2014年期间法国共有334名缺血性中风患者,其中58名有吸食大麻史的患者出现过颅内动脉狭窄症状。而对于无吸食大麻史的中风患者中,只有14.5%出现了颅内动脉狭窄的症状,这项研究结果具有重要的统计学意义。“目前,如何成功预防脑中风的发生在国际上依然是一个难以解

PLoS One:天津农村地区卒中发生率及卒中类型的调查(1992-2012)

背景:在中国城市中缺血性卒中发生增加,出血性卒中发生下降;然而, 在农村地区的趋势尚不清楚。研究者旨在探索中国农村地区卒中的发生率及卒中类型的改变得趋势。方法:通过人群为基础的卒中调查的天津大脑研究。从1985年共有14538名居民在天津乡冀县。研究者调查年龄标准化的卒中发生率(性别特异,类型特异及年龄特异),因为该地区1992年可用神经影像学检查,记录1992-1998, 1999-2005及2

JAMA Neurol:静脉溶栓前接受抗血小板治疗的患者,颅内出血发生率较高,但预后较好

重要性:静脉组织纤溶酶原激活物(tPA)治疗可改善缺血性卒中的预后;然而,许多患者在急性缺血性卒中前接受了抗血小板治疗,当进行tPA治疗时可能会增加出血的风险。目的:评估进行静脉tPA治疗的缺血性卒中患者在卒中前接受抗血小板治疗患者的风险和收益。设计:这项观察性研究应用美国心脏病协会,美国卒中协会获得指南卒中登记的数据,2009年1月到2015年3月31期间,在1545注册医院中接受tPA治疗的缺

Baidu
map
Baidu
map
Baidu
map